Literature DB >> 29097496

Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Sophie Voruz1, Anne Cairoli1, Olaia Naveiras1, Laurence de Leval2, Edoardo Missiaglia2, Krisztian Homicsko3, Olivier Michielin3, Sabine Blum4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29097496      PMCID： PMC5777214          DOI： 10.3324/haematol.2017.179150

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation.

Authors:  Hideki Tsujimura; Toshiko Miyaki; Shuhei Yamada; Takeaki Sugawara; Mikiko Ise; Shintaro Iwata; Tsukasa Yonemoto; Dai Ikebe; Makiko Itami; Kyoya Kumagai
Journal:  Int J Hematol       Date:  2014-07-26       Impact factor: 2.490

Review 2.  Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature.

Authors:  Usama Gergis; Hendrik Dax; Ellen Ritchie; Rachel Marcus; Usama Wissa; Attilio Orazi
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

3.  Thalidomide therapy for aggressive histiocytic lesions in the pediatric population.

Authors:  Kelly M Bailey; Valerie P Castle; Jennifer M Hummel; Morand Piert; Judith Moyer; Linda M McAllister-Lucas
Journal:  J Pediatr Hematol Oncol       Date:  2012-08       Impact factor: 1.289

4.  Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab.

Authors:  Neerav Shukla; Rachel Kobos; Thomas Renaud; Julie Teruya-Feldstein; Anita Price; Linda McAllister-Lucas; Peter Steinherz
Journal:  Cancer       Date:  2011-12-13       Impact factor: 6.860

5.  Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.

Authors:  S A Pileri; T M Grogan; N L Harris; P Banks; E Campo; J K C Chan; R D Favera; G Delsol; C De Wolf-Peeters; B Falini; R D Gascoyne; P Gaulard; K C Gatter; P G Isaacson; E S Jaffe; P Kluin; D M Knowles; D Y Mason; S Mori; H-K Müller-Hermelink; M A Piris; E Ralfkiaer; H Stein; I-J Su; R A Warnke; L M Weiss
Journal:  Histopathology       Date:  2002-07       Impact factor: 5.087

6.  Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma.

Authors:  Amer Zeidan; Javier Bolaños-Meade; Yvette Kasamon; Joseph Aoki; Michael Borowitz; Lode Swinnen; Heather Symons; Leo Luznik; Ephraim Fuchs; Richard Jones; Richard Ambinder
Journal:  Leuk Lymphoma       Date:  2012-08-27

7.  Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy.

Authors:  Jason L Hornick; Elaine S Jaffe; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2004-09       Impact factor: 6.394

8.  Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.

Authors:  Muneer H Abidi; Isaacson Tove; Rami B Ibrahim; Dan Maria; Edward Peres
Journal:  Am J Hematol       Date:  2007-10       Impact factor: 10.047

9.  Somatic mutations in histiocytic sarcoma identified by next generation sequencing.

Authors:  Qingqing Liu; Keith Tomaszewicz; Lloyd Hutchinson; Jason L Hornick; Bruce Woda; Hongbo Yu
Journal:  Virchows Arch       Date:  2016-06-03       Impact factor: 4.064

Review 10.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Curr Opin Genet Dev       Date:  2009-05-19       Impact factor: 5.578
View more
  8 in total

1.  Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".

Authors:  Sophie Voruz; Filipe Martins; Anne Cairoli; Olaia Naveiras; Krisztian Homicsko; Edoardo Missiaglia; Laurence de Leval; Bettina Bisig; Olivier Michielin; Sabine Blum
Journal:  Haematologica       Date:  2018-03       Impact factor: 9.941

2.  A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab.

Authors:  Yu Furui; Takashi Kurata; Kazutoshi Komori; Eriko Uchida; Yosuke Miyairi; Akihiro Chiba; Yoshifumi Ogiso; Kazuo Sakashita
Journal:  Int Cancer Conf J       Date:  2022-06-30

3.  Primary splenic histiocytic sarcoma successfully treated with splenectomy: a case report and literature review.

Authors:  Masayuki Kobayashi; Keita Sugawara; Ken Suzaki; Nobuharu Kosugi
Journal:  Int Cancer Conf J       Date:  2022-04-16

4.  Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma.

Authors:  Shree Bose; Joanna Robles; Chad M McCall; Anand S Lagoo; Daniel S Wechsler; Gary R Schooler; David Van Mater
Journal:  Pediatr Blood Cancer       Date:  2018-09-30       Impact factor: 3.167

5.  A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.

Authors:  Tadashi Kumamoto; Yuki Aoki; Tomoko Sonoda; Miho Yamanishi; Ayumu Arakawa; Masanaka Sugiyama; Nami Shirakawa; Sae Ishimaru; Yoshimasa Saito; Akiko Maeshima; Miho Maeda; Chitose Ogawa
Journal:  Int J Hematol       Date:  2018-10-25       Impact factor: 2.490

6.  Rare myeloid sarcoma with KMT2A (MLL)-ELL fusion presenting as a vaginal wall mass.

Authors:  Haiyan Bao; Juehua Gao; Yi-Hua Chen; Jessica K Altman; Olga Frankfurt; Amanda L Wilson; Madina Sukhanova; Qing Chen; Xinyan Lu
Journal:  Diagn Pathol       Date:  2019-03-28       Impact factor: 2.644

7.  Case Report: Long-Term Response to Radiotherapy Combined With Targeted Therapy in Histiocytic Sarcoma Harboring Mutations in MAPK and PI3K/AKT Pathways.

Authors:  Zijian Liu; Yin Xiao; Xinxiu Liu; Qiuhui Li; Tao Liu; Fang Zhu; Gang Wu; Liling Zhang
Journal:  Front Oncol       Date:  2021-12-06       Impact factor: 6.244

Review 8.  2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma.

Authors:  Anna Maria Frezza; Alex T J Lee; Eran Nizri; Marta Sbaraglia; Robin L Jones; Alessandro Gronchi; Angelo Paolo Dei Tos; Paolo G Casali
Journal:  ESMO Open       Date:  2018-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.